Immunotherapy Offers New Optimism for Patients With Merkel Cell Carcinoma
BY Danielle Bucco
Although chemotherapy has been used to treat patients with Merkel cell carcinoma, immunotherapy agents show great promise, according findings presented at the 2017 World Congress of Melanoma.
Excitement Grows for Immunotherapy in Lung Cancer
BY Angelica Welch
A number of patients with lung cancer have benefitted from immunotherapy agents, and researchers in the field are excited that these treatments will continue to improve the field.
Breaking Down Misconceptions About Glioblastoma
BY David Reardon, M.D.

David Reardon, M.D., clinical director at the Center for Neuro-oncology at the Dana-Farber Cancer Institute, breaks down a common misconception that many people have about glioblastoma (GBM).
When to Stop Immunotherapy Treatment for Melanoma
BY Yania Jansen
Yania Jansen, surgical trainee at Vrije Universiteit Brussel, in Brussels, Belgium, discusses the possibility of stopping treatment with Keytruda (pembrolizumab) for patients with melanoma.
Immunotherapy: Seeking a Cure With Caution
BY Kim Johnson
Immunotherapy agents are promising in the treatment of cancer, but also come with some awful side effects.
Keytruda Shows Benefit in Small Cell Lung Cancer
BY Jason Harris
The immunotherapy agent Keytruda (pembrolizumab) had an overall response rate (ORR) of 33 percent in a recent trial including patients with extensive-stage small cell lung cancer (SCLC). Findings of the phase 1b KEYNOTE-028 trial were published in the Journal of Clinical Oncology.
Questions Remain on Immunotherapy Use in Lung Cancer
BY Danielle Bucco
David R. Gandara, M.D., discusses the latest immunotherapy advances in lung cancer, as well as the next steps toward optimizing the use of these agents.
Glioblastoma Vaccine to Be Tested as Orphan Drug, Easing Clinical Trials Process
BY Thomas Keenan
The designation recognizes that the vaccine, an immunotherapy called SurVaxM, would treat a rare disease, defined as one that affects a patient population of less than 200,000 Americans. However, because it acts on a protein that appears in 80 percent of cancers generally, SurVaxM may have wider applications.  
Immunotherapy Treatment Advances in Anal Cancer
BY Meeri Kim
More personalized approaches are being developed to treat patients with metastatic disease.
When Cancer Says
BY Kelly Irvin
Scoring the big NED often leads to that "Terminator" voice whispering in your ear.
Special Feature
Share Your Art
Talk about this article with other patients, caregivers, and advocates in the Immunotherapy CURE discussion group.
Search Cancer Drugs & Terms
//For side ad protocol